Clinical Trial Update: A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase Ib/II clinical trial evaluating ATG-022 in combination with pembrolizumab, with or without chemotherapy, for CLDN18.2-positive, HER2-negative unresectab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• ATG-022
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Antengene Biologics Limited | Conditions: Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING